prodchem
Aug 19, 2026
India’s pharmaceutical industry is increasingly strengthening its capabilities in contract development and manufacturing services (CDMO), creating additional support for domestic drug development programs. The growing availability of CDMO capacity is particularly relevant to oncology, where pharmaceutical companies and biotechnology firms require specialized manufacturing, analytical, and development capabilities to advance clinical candidates.
As India’s oncology pipeline expands, domestic CDMOs are becoming an increasingly important part of the ecosystem supporting clinical-stage drug development.
CDMOs provide pharmaceutical and biotechnology companies with development and manufacturing services without requiring developers to establish all production infrastructure internally. These services can include process development, analytical testing, formulation development, clinical-trial material manufacturing, and scale-up.
For oncology programs, such capabilities can be particularly valuable because drug candidates often require specialized handling, controlled manufacturing environments, and consistent production during different stages of clinical development.
The availability of domestic CDMO capacity can therefore help Indian developers move candidates from laboratory research toward clinical trials more efficiently.
Clinical trials require a reliable supply of investigational products that meet appropriate quality and manufacturing standards. Domestic CDMOs can support this requirement by producing clinical-trial materials and helping developers establish reproducible manufacturing processes.
This is particularly important for early-stage oncology programs, where companies may need relatively small but highly controlled batches before progressing toward larger-scale production.
By providing these capabilities within India, CDMOs can help reduce dependence on overseas manufacturing and potentially improve coordination between drug developers, clinical research organizations, hospitals, and manufacturing partners.
India’s oncology sector is becoming increasingly active as pharmaceutical companies and biotechnology firms explore innovative treatments, biosimilars, targeted therapies, and other cancer-related products.
The country’s established pharmaceutical manufacturing base provides an important foundation for this growth. Increasing investment in research and development is also creating demand for specialized partners capable of supporting drug candidates throughout development.
For CDMOs, this creates opportunities to participate earlier in the pharmaceutical value chain, moving beyond conventional manufacturing toward integrated development and clinical-support services.
The expansion of domestic CDMO capabilities can provide several potential advantages to oncology developers.
Working with domestic manufacturing partners can simplify communication and coordination between development teams and production facilities, particularly during early clinical stages.
Local manufacturing can reduce exposure to international logistics disruptions, overseas production constraints, and extended transportation timelines.
India’s established pharmaceutical manufacturing ecosystem can offer competitive development and manufacturing costs, although actual savings depend on the complexity of the product and required technologies.
As Indian CDMOs invest in advanced manufacturing capabilities, they can provide specialized expertise in areas such as process development, analytical characterization, formulation, and scale-up.
Despite the growing capacity, oncology-focused CDMO development also faces several challenges. Manufacturing complex therapies can require significant investment in specialized facilities, quality systems, technical personnel, and regulatory compliance.
Companies must also maintain consistent product quality while scaling production from early clinical batches toward later-stage and commercial manufacturing.
Regulatory expectations, intellectual property protection, technology transfer, and supply-chain reliability remain important considerations when pharmaceutical developers select a CDMO partner.
The growth of domestic CDMO capacity could strengthen India’s position across the pharmaceutical development value chain. Rather than serving primarily as a manufacturing base, India has an opportunity to become a more integrated hub for drug discovery, clinical development, manufacturing, and commercialization.
For oncology in particular, stronger domestic infrastructure could support more locally developed candidates and increase collaboration between pharmaceutical companies, biotechnology firms, hospitals, research institutions, and manufacturing organizations.
As India’s oncology pipeline continues to develop, demand for specialized development and manufacturing services is likely to remain an important growth opportunity for domestic CDMOs.
Companies that can combine strong quality systems with advanced manufacturing capabilities, regulatory expertise, analytical services, and flexible clinical-trial production may be well positioned to support emerging oncology programs.
The continued expansion of this ecosystem could help Indian developers progress promising candidates through clinical development while strengthening the country’s broader pharmaceutical innovation infrastructure.
India’s growing CDMO capacity is becoming an important component of the country’s evolving oncology development ecosystem. By providing clinical-trial manufacturing, development expertise, analytical support, and scalable production capabilities, domestic CDMOs can help pharmaceutical and biotechnology companies advance oncology candidates through critical development stages.
As investment in cancer research and innovative medicines increases, the relationship between oncology drug developers and domestic CDMOs is likely to become increasingly important. Stronger local development and manufacturing capabilities could ultimately support India’s ambitions to play a larger role in global pharmaceutical innovation.
Featured Product
Found this useful?
Continue Reading
Ongoing California litigation involving DuPont's spin-off structure highlights a broader procurement question about supplier continuity and counterparty risk. Chemical buyers may need to examine corporate separations more closely when evaluating newly independent suppliers.
DuPont's use of a pre-funded PFAS escrow account for its first 2026 New Jersey settlement payment highlights how chemical companies can combine accounting reserves, dedicated cash and financial guarantees to manage long-term environmental liabilities.
A new CDSCO filing for a Triple Negative Breast Cancer molecule adds to India's growing 2026 oncology pipeline and highlights the country's broader shift toward innovative pharmaceutical development.
